# Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants

> **NCT00937404** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 25 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Poliorix

## Key facts

- **NCT ID:** NCT00937404
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08-04
- **Primary completion:** 2009-11-13
- **Final completion:** 2009-11-13
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2018-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937404, "Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00937404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*